BD Unveils Nebraska-Based Manufacturing Capacity to Support U.S. Vaccination Agility and Preparedness

This week, in a letter to Senate Majority Leader Chuck Schumer, AdvaMed President and CEO Scott Whitaker underscored the critical importance of passing a tax provision that allows small businesses to deduct their research and development expenses in the year the expense was incurred. AdvaMed, the world’s largest trade association representing medical technology companies, supports the provision, which until 2022, encouraged small companies and startups to continue investing in R&D, the lifeblood of these primarily pre-commercial companies.

Artificial intelligence has been in the spotlight recently, but it is not a new concept to the Food and Drug Administration (FDA) or the medtech industry. AI advancements in the medtech industry are playing a major role in improving patients’ lives through innovative care, reduced healthcare costs, and improved patient outcomes.

Today, Zach Rothstein, Executive Director of AdvaMedDx, testified before the House Energy and Commerce Committee, Subcommittee on Health during a hearing on diagnostic test regulation and FDA’s proposed laboratory developed test (LDT) rule.

Former U.S. Senator Richard Burr of North Carolina joined me on the Medtech POV podcast to share his perspective on policy and leadership. Having served in the U.S. House and Senate for nearly three decades, including tenure as Ranking Member of the Senate Committee on Health, Education, Labor and Pensions (HELP), he’s an expert on health care policy. He also has a historical perspective that anyone involved in health-care policy should value. 

Scott Whitaker, President and CEO of AdvaMed, the Medtech Association, sent a letter to CMS Administrator Chiquita Brooks-LaSure outlining industry disappointment in the lack of a finalized rule for Transitional Coverage for Emerging Technology.

By Friday, March 1, the Environmental Protection Agency is expected to finalize its regulation for the ethylene oxide (EtO) sterilization of 20 billion, or half, of all medical devices in the United States each year. AdvaMed President and CEO Scott Whitaker released the following statement:

Today, AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker on the potential government shutdown and the impact it could have on patients: